Velusetrag

Velusetrag (also known as TD-5108) is a serotonin receptor agonist developed by Theravance Biopharma for the treatment of gastrointestinal disorders. It is currently in clinical trials for the treatment of gastroparesis and chronic constipation.

History

Velusetrag was initially developed by Theravance Biopharma, a biopharmaceutical company focused on the creation of small molecule medicines. The drug is currently in the late stages of clinical trials.

Mechanism of Action

Velusetrag works by stimulating the 5-HT4 receptor, a type of serotonin receptor found in the gastrointestinal tract. This stimulation increases the movement of the intestines, helping to speed up the passage of food through the stomach.

Clinical Trials

Velusetrag has undergone several clinical trials for the treatment of gastroparesis and chronic constipation. In a Phase 2 trial, the drug was found to significantly improve gastric emptying and symptoms in patients with gastroparesis. A Phase 3 trial is currently underway.

Side Effects

Common side effects of Velusetrag include nausea, diarrhea, and headache. In clinical trials, these side effects were generally mild to moderate in severity.

Future Developments

If successful in clinical trials, Velusetrag could provide a new treatment option for patients with gastroparesis and chronic constipation, conditions for which there are currently limited treatment options.

Velusetrag Resources
Latest articles Most recent articles Ongoing trials	Wikipedia